Summary.-A mouse monoclonal cell line (L1) was produced by fusing the mouse myeloma P3X63/Ag8 with CD2F1 spleen cells immunized with a highly immunogenic subline of L1210 leukaemia (Li210/DTIC). A very few positive clones (1%) were isolated and one of these was chosen for detailed study. The monoclonal antibody Li is an IgM immunoglobulin strongly reacting in a complement-dependent cytotoxicity assay against L1210/Cr leukaemia and its more or less inmmunogenic sublines. The specificity of the LI antibody against L1210 leukaemia was studied by extensive screening with normal adult and foetal tissues, lymphoid tissues from several independent strains and a panel of the most common experimental tumours, to all of which it was unreactive. Attempts at immunotherapy were carried out in DBA/2 mice challenged with L1210 leukaemia and treated with Li (ascites) and complement. Although the in vitro cytotoxic titre of ascites fluid from mice bearing hybridoma was very high (10-7), no therapeutic effect was obtained in vivo.
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TUMOUR CELLS have been shown to express surface antigens in both animal and human experimental systems. These include histocompatibility antigens and tumour-associated antigens (TAA). Since they were identified (Prehn & Main, 1957; Klein et al., 1960; Old & Boyse, 1964) , TAA have been regarded as a natural target for cancer immunotherapy. Yet immunotherapy through humoral or cellmediated manipulations has been so far ineffective (Rosenberg et al., 1977;  Hawrylko, 1978; Motta, 1971) . The failure of passive immunotherapy has been ascribed to the low immunogenicity (Hewitt et al., 1976) of TAA, fast shedding of antigen (Black, 1980) , neutralizing antigens circulating in the blood (Nadler et al., 1980a) and antigenic modulation elicited by serum itself (Boyse et al., 1967; Stackpole et al., 1980) . Although TAA have been found in a great number of tumour cells, they have not yet been well characterized molecularly. Conventional anti-tumour sera have not been com- pletely reliable for the analysis of TAAs, owing to their low affinity and low titre. Since monoclonal antibodies overcome the above limitations (Gunn et al., 1980; Simrell & Klein, 1979; Nadler et al., 1980b) , they should provide, in principle, an ideal means of study and treatment of tumours immunologically. In this paper the preparation and the characterization of a monoclonal antibody specific to an L1210 leukaemia-associated antigen is reported.
The monoclonal antibody, secreted by a mouse-mouse hybridoma, has been obtained by fusing the mouse myeloma P3X63/Ag8 cells and spleen cells from mice immune to a syngeneic highly immunogenic subline of the L1210 leukaemia.
MATERIALS AND METHODS
Mice and tumours. Inbred DBA/2, C3H, C57BL/6J, BALB/c and hybrid CD2F1 male mice, 10-15 weeks old, were obtained from Charles River (Calco, Italy) . AKR, B10.S male mice were kindly provided by Dr G. Parmiani, N.C.I., Milan, Italy. Lowimmunogenic L1210/Cr leukaemia was maintained by weekly i.p. passage in compatible CD2F1 mice. The immunogenic L1210/ DTIC sublines, obtained as previously described (Mihich & Kitano, 1971; Bonmassar et al., 1970; Nicolin et al., 1974) , were grown in CD2F1 mice immunosuppressed by 200 mg/kg cyclophosphamide i.p. 24h before challenge. The properties of the tumour cells used to assess the specificity of monoclonal antibodies are indicated in Table V and the tumours were maintained by in vivo or in vitro passages under standard methods.
Hybridization.-The hybridization technique described by Nowinski et al. (1979) has been followed, with minor modifications. Briefly, CD2F1 mice were challenged with 107 viable L1210/DTIC cells i.p. on Days 0 and 7, and i.v. on Day 17. Three days later spleen cells from immune mice were mixed with BALB/c myeloma P3X63/Ag8 cells in a ratio of 4:1 in serum-free RPMI 1640 (Eurobio, Paris, France). The mixture was centrifuged in 50ml plastic tubes (Falcon, Cockeysville, Md., U.S.A.) and the pellet resuspended in 50%/ polyethylene glycol, mol. wt 1500 (PEG 1500, Merck-Schuchardt, Hohenbrunn, W. Germany) at 37°C. The concentration of PEG was gradually decreased by the slow addition of serum-free RPMI 1640 with gentle stirring. The cell suspension was washed and resuspended in 40 ml of complete RPMI 1640 (20% foetal calf serum, Seromed, Miunchen, Germany) and distributed on 4 96-well, flat-bottomed microtitre plates (Falcon). On Days 1, 2, 4, 7 and 11 the culture medium was replaced with conditioned hypoxanthine-aminopterin-thymidine (HAT) medium (Littlefield, 1964) . Two to three weeks after fusion, 100 ,l of culture supernatant from wells with growing hybrids, as seen under the microscope, were collected for preliminary screening. Cytotoxic antibodies in hybridoma cultures were detected by the 51Cr-release assay, using 5lCr-labelled L1210/DTIC cells as targets (Cerottini et al., 1974) . Briefly, 25 ,ul containing 106 target cells/ml were exposed to 25 1l culture supernatant for 30 min at 37°C. An appropriate dilution of rabbit complement was added (25 ,ul) (Ozato et al., 1980 
RESULTS
Cell fusion and production of the monoclonal antibody Two weeks after fusion, hybrid cells were detected in 950 of the wells. Although after further growth in 24-well plates most of them lost their activity (Nowinski et al., 1979; Ozato et al., 1980) , in the early screening about 500 of positive supernatants were obtained (specific 51Cr-release 15-60%). One of 3 definitely positive hybrids, immediately minicloned, Nicolin et al. (1974) .
at 5 cells/well (Nowinski et al., 1979) , has yielded 95% positive hybrids. Cell culture were allowed to grow on a larger scale and supernatants were collected and frozen at -80°C.
Cells from 3 positive miniclones were further cloned by limiting dilution, with cloning efficiency of 10-20%, to yield 20 highly cytotoxic supernatants. Since all the supernatants showed the same pattern of reactivity and contained a monoclonal antibody of IgM subclass, a single designation, namely LI, has been adopted.
Characterization of LI reactivity
As shown in Table I , Li is cytotoxic against both L1210/Cr leukaemia and its immunogenic sublines, and the less related L1210/Ha leukaemia. The pattern of reactivity is independent of the immunogenicity of the tumour lines, as established by rejection experiments in syngeneic mice (Kitano et al., 1972; Nicolin et al., 1980 IgA (x). The residual cytotoxicity of LI was measured by 51Cr-release assay, using L1 21O/Cr as targets.
tests. The cytotoxicity of LI was completely absorbed by as few as 107 tumour cells (Fig. 1) . The titration of LI activity is shown in Fig. 2 . The cytotoxicity was much higher in the ascitic fluid, (dilution 10-6-10-7) than in the supernatants (dilution 10-3), of in vitro hybridoma cultures. Hybrids established for more than 6 months or thawed after storage at -80°C retaine(i their capacity to secrete LI.
The cytotoxicity of LI was completely removed by preincubation with goat anti-oa mouse Jg7S (ox light chains) and with goat anti-ot mouse (Q-heavy chain) (Fig. 3) . Since a single band has been obtained by standard immunoelectrophoresis (not reported here) and the inhibitory effects of other immunoglobulin subclasses were significatively less effective, LI is considered to belong to the IgM subclass.
The specificity of LI activity for L1210 leukaemia has been established by extensive screening on syngeneic and allogeneic lymphoid cells, on normal adult and foetal cells, and on a number of experimental mouse tumours. Table II shows that spleen cells from several independent strains, both syngeneic and allogeneic, failed to remove LI activity. The reactivity of LI to normal and foetal tissues was studied by the indirect fluorescence method. As shown in 398 1( t NK activity was tested in a 4 h 51Cr-release assay with 5lCr-labelled YAC-1 as target cells. Data are presented as % specific lysis, according to the formula and methods described by Cerottini (1974) .
complement, was not lysed by LI (Table  III) . In addition, LI did not modify the activity of natural killer (NK) cells (Table IV) .
Finally, the reactivity of LI was matched (Table V) (Abelson & Rabstein, 1970) was also completely unreactive. Because of its high specificity and its potent cytotoxicity in vitro, LI was used for immunotherapeutic studies in L1210-bearing animals. LI and rabbit complement were inoculated, following various schedules of treatment, into leukaemic mice challenged with L1210 cells i.p. on Day 0, but failed to improve their life t Checked in vitro for complement activity.
span over that of untreated animals (Table VI) .
DISCUSSION
The L1210 lymphoblastoid cell line is a mouse lymphoma originally induced in DBA/2 mice by exposure to methylcholanthrene (Law et al., 1949 The specificity of LI to L1210 leukaemia cells was established by its lack of reactivity with a variety of target cells and from the schedule of hybridization (syngeneic immunization and mouse-mouse fusion). In spite of the high in vitro cytotoxicity of LI and lack of toxicity to the host tissues, attempts at immunotherapy of L1210 mice were unsuccessful. Other sche 1ules of treatment, not reported here, were also ineffective. Complement inactivation in vivo, neutralization of LI by antigens circulating in the blood or present in the ascitic fluid are first among the hypotheses that should be experimentally tested in attempts to explain the negative in vivo findings. Antigenic modulation by LI itself, or poor binding to target tumour cells, might also be worth attention. Whatever the reason for the failure of these and other (Houston et al., 1980; Ritz et al., 1980 ) preliminary attempts at serological therapy, the exploitation of the monoclonal antibody technology in experimental cancer might be furthered by studies with LI. Since L1210 leukaemia has been widely used over the last 30 years and there is good knowledge of its in vivo and in vitro biological properties, studies with this experimental model might easily and quickly provide some essential pieces of information. The high specificity of LI, and its lack of reactivity to normal tissues, might make it an optimal tool in carrying toxic agents to target cells or developing experimental methodologies for highly sensitive immunodiagnosis.
